Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine: Cambridge, Massachusetts Wednesday, July 2, 2025, 16:00 Hrs [IST] Moderna, Inc ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

SunRun (RUN), and SolarEdge (SEDG) are in focus as changes to the big beautiful bill could introduce new taxes on the ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has been given an average rating of “Hold” by the twenty-three analysts that ...